Race Oncology treats first patient with RC220 in a milestone quarter
Race Oncology treats first patient with RC220 in a milestone quarter
Race Oncology chief executive officer Dr Daniel Tillett talked with Proactive about the company’s key milestones this quarter, including the treatment of the first patient with its lead asset, RC220, a reformulated version of...
Executive Chairman Dr Pete Smith Joins The Capital Compass to Discuss Breakthrough Cancer Drug RC220
Executive Chairman Dr Pete Smith Joins The Capital Compass to Discuss Breakthrough Cancer Drug RC220
In this exclusive interview with The Capital Compass, Dr. Pete Smith from Race Oncology discusses the company’s groundbreaking work on RC220, a reformulated cancer drug with a proven history of efficacy and safety. Watch...
Race Oncology doses first patient in trial of RC220 + doxorubicin for solid tumours
Race Oncology doses first patient in trial of RC220 + doxorubicin for solid tumours
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has successfully dosed the first patient with the combination of its lead drug RC220 and doxorubicin in its Phase 1 clinical trial targeting advanced solid tumours. Read the full article...
The Australian: Race Oncology doses first patient in RC220 Phase 1 solid tumour trial
The Australian: Race Oncology doses first patient in RC220 Phase 1 solid tumour trial
The Australian reports Race Oncology has achieved a major milestone, as the company has safely and successfully dosed its first patients for its Phase 1 clinical trial in advanced solid tumours. Read the full...
ausbiz: Race to better cancer treatment
ausbiz: Race to better cancer treatment
Race CEO and Managing Director Dr Daniel Tillett speaks with ausbiz about the company’s recent major milestone – the first patient has been safely and successfully dosed for the RC220 Phase 1 clinical trial...
Race Oncology launches Phase I RC220 trial in Australia
Race Oncology launches Phase I RC220 trial in Australia
Race Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is...
Stockhead reports Race gets ethics nod for Phase I trial in solid tumour patients
Stockhead reports Race gets ethics nod for Phase I trial in solid tumour patients
Race Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via...
Proactive: Race Oncology’s RC220 trial gets green light
Proactive: Race Oncology’s RC220 trial gets green light
Race Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with...
ausbiz speaks with Race CEO on the Phase 1 trial ethics approval
ausbiz speaks with Race CEO on the Phase 1 trial ethics approval
Race CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial. Watch the full video via this link....
Proactive – Daniel Tillett on Race Oncology’s drug advancements
Proactive – Daniel Tillett on Race Oncology’s drug advancements
Race CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe...
